Sinopharm Group Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Sinopharm Group kazanç ve gelirin sırasıyla yıllık 6.3% ve 5.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 6.3% olacağı tahmin edilmektedir.
Anahtar bilgiler
6.3%
Kazanç büyüme oranı
6.5%
EPS büyüme oranı
| Healthcare kazanç büyümesi | 22.1% |
| Gelir büyüme oranı | 5.9% |
| Gelecekteki özkaynak getirisi | 6.3% |
| Analist kapsamı | Good |
| Son güncelleme | 31 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 698,276 | 10,026 | 12,706 | 13,062 | 14 |
| 12/31/2025 | 650,544 | 9,223 | 12,286 | 12,432 | 16 |
| 12/31/2024 | 604,751 | 8,174 | 21,344 | 15,575 | 13 |
| 9/30/2024 | 593,073 | 8,236 | 6,811 | 9,125 | N/A |
| 6/30/2024 | 590,346 | 8,653 | 16,768 | 19,506 | N/A |
| 3/31/2024 | 598,318 | 8,884 | 8,035 | 10,385 | N/A |
| 12/31/2023 | 596,570 | 9,054 | 14,889 | 17,173 | N/A |
| 9/30/2023 | 591,686 | 8,765 | 10,526 | 12,722 | N/A |
| 6/30/2023 | 591,626 | 8,936 | 9,660 | 11,931 | N/A |
| 3/31/2023 | 570,067 | 8,688 | 14,469 | 16,763 | N/A |
| 12/31/2022 | 552,148 | 8,526 | 18,648 | 20,964 | N/A |
| 9/30/2022 | 546,147 | 7,914 | 6,159 | 8,507 | N/A |
| 6/30/2022 | 533,403 | 7,870 | 492 | 2,783 | N/A |
| 3/31/2022 | 528,383 | 7,970 | 5,378 | 7,658 | N/A |
| 12/31/2021 | 521,051 | 7,759 | 7,081 | 9,308 | N/A |
| 9/30/2021 | 510,091 | 7,930 | 4,511 | 6,795 | N/A |
| 6/30/2021 | 501,770 | 7,874 | 8,743 | 10,983 | N/A |
| 3/31/2021 | 482,281 | 7,591 | 5,833 | 7,950 | N/A |
| 12/31/2020 | 456,415 | 7,187 | 9,099 | 11,155 | N/A |
| 9/30/2020 | 440,194 | 6,615 | 5,998 | 8,075 | N/A |
| 6/30/2020 | 427,372 | 6,174 | 2,304 | 4,522 | N/A |
| 3/31/2020 | 424,494 | 5,918 | 6,510 | 8,813 | N/A |
| 12/31/2019 | 425,273 | 6,251 | 16,417 | 18,777 | N/A |
| 9/30/2019 | 406,394 | 6,311 | -5 | 2,113 | N/A |
| 6/30/2019 | 382,717 | 6,012 | -224 | 1,744 | N/A |
| 3/31/2019 | 360,760 | 6,087 | -5,010 | -3,011 | N/A |
| 12/31/2018 | 344,526 | 5,834 | 392 | 3,654 | N/A |
| 9/30/2018 | 336,113 | 5,523 | -9,906 | -6,868 | N/A |
| 6/30/2018 | 334,060 | 5,606 | N/A | 2,882 | N/A |
| 3/31/2018 | 318,414 | 5,083 | N/A | -6,249 | N/A |
| 12/31/2017 | 308,354 | 5,572 | N/A | 3,209 | N/A |
| 9/30/2017 | 288,855 | 5,217 | N/A | -19 | N/A |
| 6/30/2017 | 269,356 | 4,861 | N/A | -3,247 | N/A |
| 3/31/2017 | 264,691 | 4,996 | N/A | N/A | N/A |
| 12/31/2016 | 258,388 | 4,635 | N/A | 9,258 | N/A |
| 9/30/2016 | 251,401 | 4,515 | N/A | 11,117 | N/A |
| 6/30/2016 | 244,414 | 4,394 | N/A | 12,975 | N/A |
| 3/31/2016 | 234,499 | 3,885 | N/A | N/A | N/A |
| 12/31/2015 | 228,673 | 3,772 | N/A | 13,412 | N/A |
| 9/30/2015 | 222,513 | 3,548 | N/A | 9,472 | N/A |
| 6/30/2015 | 216,353 | 3,323 | N/A | 5,533 | N/A |
| 3/31/2015 | 207,865 | 3,037 | N/A | N/A | N/A |
| 12/31/2014 | 200,131 | 2,875 | N/A | 5,561 | N/A |
| 9/30/2014 | 190,883 | 2,719 | N/A | 5,747 | N/A |
| 6/30/2014 | 181,635 | 2,564 | N/A | 5,933 | N/A |
| 3/31/2014 | 174,251 | 2,407 | N/A | 5,437 | N/A |
| 12/31/2013 | 166,866 | 2,250 | N/A | 4,941 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 1099 'nin tahmini kazanç büyümesi (yıllık 6.3% ) tasarruf oranının ( 2.3% ) üzerindedir.
Kazançlar ve Piyasa: 1099 şirketinin kazançlarının (yıllık 6.3% ) Hong Kong pazarından (yıllık 11.5% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: 1099 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: 1099 şirketinin gelirinin (yıllık 5.9% ) Hong Kong pazarından (yıllık 7.8% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 1099 şirketinin gelirinin (yıllık 5.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 1099 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 6.3 %).